Brazil benefits from a program, known as the Partnership for Productive Development, that brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of high-cost biologics that account for approximately half of annual drug spending.
In 2010, Brazil’s National Health Surveillance Agency (ANVISA) established criteria for biosimilar approval, forming a comprehensive pathway for these products for the first time. The guidelines, Collegiate Board Resolution 55/2010, provides 2 ways in which a biosimilar can be approved: comparability and individual development.
The comparability demonstration is similar to that described by the World Health Organization. Under Brazil’s comparability pathway, biosimilars require comparative data from preclinical as well as phase 1 and phase 3 clinical studies in relation to the reference product, and the extrapolation of indications is permitted. Robust pharmacovigilance systems, similar to those in place for the reference drug, are required.
Read more about biosimilars in Brazil.
However, the individual development pathway differs significantly from the comparability pathway; individual development requires comparative data only from preclinical trials and phase 3 confirmatory studies, with no requirement to produce comparative data from phase 1 studies. Extrapolation of indications for products developed in this manner are not permitted, and these products may not be treated as interchangeable with their references.
For both types of biosimilar products, explains a newly published paper, Brazil benefits from a program known as the Partnership for Productive Development (PPD), which brings together government and the private sector to develop strategic products of interest to the Brazilian health system—including biosimilars of the high-cost biologics that account for approximately half of annual drug spending.
In an arrangement that the paper calls a “win-win opportunity” for both government and private companies, under a PPD agreement, the master cell bank for a biologic is required by law to be transferred to the government organization participating in the agreement for use in manufacturing, and the biosimilar maker develops a product that will then be purchased directly by the Brazilian Ministry of Health. Thus, the government establishes a supply of a cost-reducing product, and the biosimilar developer ensures robust sales of its product. Biosimilars that are currently part of such agreements include rituximab, adalimumab, and bevacizumab.
The impact of such agreements on Brazil’s healthcare system has the potential to be significant. At the same time, nationalizing production of biosimilars presents an opportunity, say the paper's authors, for the nation to positive impact its trade balance, generate tax revenue, and provide jobs in Brazil.
Reference
Scheinberg MA, Felix PAO, Kos IA, Andrade MA, Azevedo VF. Partnership for productive development of biosimilar products: perspective of access to biological products in the Brazilian market. Einstein (Sao Paulo). 2018;16(3): eRW4175. doi: 10.1590/S1679-45082018RW4175.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
IQVIA Webinar: Enhancing Regulatory Strategies for Biosimilars and Generics
October 14th 2024During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies for navigating complex approval processes, the importance of local market understanding, and the role of technology in enhancing submission efficiency.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.